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ABSTRACT The human persistent and oncogenic Epstein-Barr virus (EBV) was one
of the ﬁrst viruses that were described to express viral microRNAs (miRNAs). These
have been proposed to modulate many host and viral functions, but their predomi-
nant role in vivo has remained unclear. We compared recombinant EBVs expressing
or lacking miRNAs during in vivo infection of mice with reconstituted human im-
mune system components and found that miRNA-deﬁcient EBV replicates to lower
viral titers with decreased frequencies of proliferating EBV-infected B cells. In re-
sponse, activated cytotoxic EBV-speciﬁc T cells expand to lower frequencies than
during infection with miRNA-expressing EBV. However, when we depleted CD8 T
cells the miRNA-deﬁcient virus reached similar viral loads as wild-type EBV, increas-
ing by more than 200-fold in the spleens of infected animals. Furthermore, CD8 T
cell depletion resulted in lymphoma formation in the majority of animals after
miRNA-deﬁcient EBV infection, while no tumors emerged when CD8 T cells were
present. Thus, miRNAs mainly serve the purpose of immune evasion from T cells
in vivo and could become a therapeutic target to render EBV-associated malignan-
cies more immunogenic.
IMPORTANCE Epstein-Barr virus (EBV) infects the majority of the human population
and usually persists asymptomatically within its host. Nevertheless, EBV is the caus-
ative agent for infectious mononucleosis (IM) and for lymphoproliferative disorders,
including Burkitt and Hodgkin lymphomas. The immune system of the infected host
is thought to prevent tumor formation in healthy virus carriers. EBV was one of the
ﬁrst viruses described to express miRNAs, and many host and viral targets were
identiﬁed for these in vitro. However, their role during EBV infection in vivo re-
mained unclear. This work is the ﬁrst to describe that EBV miRNAs mainly increase
viremia and virus-associated lymphomas through dampening antigen recognition by
adaptive immune responses in mice with reconstituted immune responses. Cur-
rently, there is no prophylactic or therapeutic treatment to restrict IM or EBV-
associated malignancies; thus, targeting EBV miRNAs could promote immune re-
sponses and limit EBV-associated pathologies.
KEYWORDS Epstein-Barr virus, cytotoxic T cells, humanized mice, immune escape,
lymphoma, miRNA
Epstein-Barr virus (EBV) is a ubiquitous human gammaherpesvirus that is carried bythe majority of the adult human population as an asymptomatic but persistent
infection (1). At the same time, it is one of the most growth-transforming infectious
agents and the only one that can readily immortalize its main host cell, the human B
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cell, in culture (2). Accordingly, EBV is associated with lymphomas and epithelial cell
cancers, which express different subsets of latent EBV gene products. Diffuse large B cell
lymphomas and in vitro-transformed lymphoblastoid cell lines (LCLs) are positive for six
EBV nuclear antigens (EBNAs), two latent membrane proteins (LMPs), two nontranslated
Epstein-Barr virus-expressed RNAs (EBERs), and two clusters of microRNAs (miRNAs), the
smaller BHRF1 miRNA cluster (3 pre-miRNAs) and the larger BART miRNA cluster (22
pre-miRNAs), giving rise to at least 44 mature miRNAs (3). Only one EBNA (EBNA1) and
the two LMPs can be found in classical Hodgkin lymphoma and nasopharyngeal
carcinoma, but all nontranslated RNAs are expressed. Finally, Burkitt lymphoma and
EBV-associated gastric carcinoma further downregulate latent EBV protein expression
and are positive only for EBNA1 but continue to express the nontranslated RNAs. These
expression patterns in EBV-associated malignancies are mirrored in B cell differentiation
stages of healthy EBV carriers (4). In quiescent memory B cells, EBV protein expression
is abolished altogether and only nontranslated EBV RNAs are expressed. This docu-
ments the importance of EBERs and viral miRNAs for all latent and growth-transforming
stages of EBV infection.
Fortunately, even though all premalignant EBV infection patterns are present in
healthy EBV carriers, only a very small fraction of infected individuals develop virus-
associated tumors, with an estimated incidence rate of 200,000 new cases of EBV-
associated malignancies annually (5). It is thought that the immune system prevents
EBV-driven tumor development, because EBV-associated lymphomas occur at increased
frequencies in primary and acquired immunodeﬁciencies (6, 7). Acquired immunode-
ﬁciency due to HIV coinfection and primary immunodeﬁciencies due to mutations in
the cytotoxic machinery, lymphocyte costimulation, and T cell receptor signaling
identify CD8 T cells as the crucial immune compartments for the control of EBV
infection and prevention of associated lymphomagenesis. Accordingly, some EBV-
associated tumors can be cured by adoptive transfer of EBV-speciﬁc T cell lines (8).
Furthermore, in preclinical in vivomodels of persistent EBV infection, utilizing mice with
reconstituted human immune system components (huNSG mice), T cell depletion leads
to increased viral loads and lymphoma formation (9–11). EBV seems to strike the right
balance, ensuring its persistence after primary infection and allowing sufﬁcient immune
control to protect its host. Therefore, it is perhaps not surprising that it has been found
in vitro that EBV-expressed miRNAs also regulate this T-cell-mediated immune control
and dampen antigen presentation on major histocompatibility complex (MHC) class I
and II molecules to CD8 and CD4 T cells, respectively (12, 13). However, the
importance of this immune evasion by EBV-contained miRNAs remains unclear in vivo.
In order to address this question, we explored recombinant Epstein-Barr viruses,
lacking either the larger BART cluster of miRNAs or all EBV-expressed miRNAs. In the
absence of all EBV miRNAs, the virus established much lower viral titers after infection
of huNSG mice. Surprisingly, CD8 T cell depletion restored EBV infection to titers
comparable to wild-type virus infection, causing an increase in viral loads by more than
200-fold in the spleen and lymphoma formation in the majority of infected animals. Our
ﬁndings suggest that EBV-expressed miRNAs mainly serve the purpose of compromis-
ing T-cell-mediated immune control and highlight the importance of this immune
control in the prevention of EBV-associated lymphoma formation.
RESULTS
EBV infection is attenuated in the absence of viral miRNAs. EBV devoid of its
BHRF1 miRNA locus has previously been shown to delay systemic infection in a
humanized mouse model without altering the tumor formation capacity of EBV (14). To
further investigate the role of EBV miRNA in vivo, we used recombinant EBV strains that
lack all EBV miRNAs (ΔmiR) (15) or only BART miRNAs (ΔmiR-BART) to infect NOD-scid
c
null mice with reconstituted human immune system compartments (huNSG mice).
Our group and others have previously shown that the huNSG mouse model is a suitable
model for EBV infection and cell-mediated immune control in vivo (9–11, 16–19). In
order to determine the pathogenic potential of ΔmiR and ΔmiR-BART EBV, we inocu-
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lated huNSG mice with 105 Raji-infectious units (RIU) of the respective viruses and
monitored infection compared to wild-type (wt) EBV for 5 to 6 weeks. The viral DNA
burden was signiﬁcantly lower in mice infected with ΔmiR than with wt EBV, but
comparable between ΔmiR-BART and wt EBV over the entire observation period in
blood, starting at 3 weeks after infection when viral loads became reliably detectable
for the ﬁrst time (Fig. 1A and C), and at the end of the experiments in spleen (Fig. 1B
and D). Hence, these data suggest that ΔmiR EBV has a reduced, whereas ΔmiR-BART
EBV has a similar, infectious capacity compared to wt EBV.
Reduced frequencies of proliferating EBV-infected cells in the absence of viral
miRNAs. Next, we investigated if the reduced titers of EBV in the absence of its miRNAs
are due to decreased proliferation or increased apoptosis. Primary B cells infected with
EBV lacking BHRF1 miRNAs were shown to undergo increased apoptotic death and
decreased proliferation during the early infection period in vitro (15, 20). We therefore
examined the frequency of proliferating and apoptotic cells in EBV-infected cells in our
in vivo system using splenic sections of wt and ΔmiR EBV-infected mice. Immunohis-
tochemical analysis of costaining for cleaved caspase 3 (cl. Cas3) and the viral protein
EBNA2 suggested that there was less apoptotic activity in ΔmiR-infected cells than in
wt-infected cells, although this difference did not reach statistical signiﬁcance (Fig. 2A
and B). Overall, the level of cl. Cas3 EBNA2 cells was very low (Fig. 2A). Immunoﬂu-
orescence costaining for Ki67 and EBNA2 revealed a signiﬁcantly higher frequency of
proliferating EBNA2-positive cells in wt- than in ΔmiR-infected mice (Fig. 2C and D).
However, established LCLs generated in vitro with either wt or ΔmiR EBV did not show
a growth difference when quantifying total cell numbers over 12 consecutive days (see
Fig. S1 in the supplemental material). These results indicate that reduced viral titers in
the absence of EBV miRNA might be due to reduced proliferation of infected cells or
other factors, such as increased immune control of proliferating infected cells.
Activation and memory formation of CD8 T cells correlate with EBV viral load.
Infection of huNSG mice with wt EBV has been reported to induce the activation and
FIG 1 EBV infection is attenuated in the absence of viral miRNAs. (A and C) Blood DNA viral loads over time as
determined by qPCR of huNSG mice infected with either wt, ΔmiR (A), or ΔmiR-BART (C) EBV for 5 to 6weeks
(n 14 to 21/group). The horizontal dashed line indicates the lower limit of quantiﬁcation (LLOQ). Values below
the LLOQ were raised to the LLOQ and plotted on the LLOQ line. (B and D) Splenic endpoint viral DNA loads as
determined by qPCR of huNSG mice infected with either wt, ΔmiR (B), or ΔmiR-BART (D) EBV for 5 to 6weeks
(n  12 to 16/group). (A to D) Pooled data from 4wt and ΔmiR-BART and 6wt and ΔmiR experiments are
displayed with geometric mean. *, P 0.05; **, P 0.01; ***, P 0.001, Mann-Whitney U test.
Immune Escape by EBV miRNAs ®
January/February 2019 Volume 10 Issue 1 e01941-18 mbio.asm.org 3
 o
n
 January 30, 2020 at UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://m
bio.asm
.org/
D
ow
nloaded from
 
expansion of human CD8 T cells in huNSG mice (10, 19). Since EBV miRNAs control
adaptive antiviral immunity in vitro (12, 13), we assessed T cell activation and memory
formation upon infection with ΔmiR, ΔmiR-BART, and wt EBV in vivo. In line with the
EBV DNA burden in blood and spleen (Fig. 1), we detected similar frequencies of
HLA-DR CD45RO CD4 T cells (Fig. 3A and Fig. S2A, right panels) and HLA-DR
CD45RO CD8 T cells (Fig. 3B and Fig. S2B, right panels) in mice infected with wt and
ΔmiR-BART EBV, whereas mice infected with ΔmiR EBV showed reduced frequencies
compared to wt EBV 5 to 6 weeks postinfection (p.i.) (Fig. 3A and B, left panels, and
Fig. S2A and B, left panels). Investigating speciﬁcally the formation of effector or central
memory CD8 T cells, frequencies of blood and splenic effector memory (CCR7
CD45RA) CD8 T cells were increased in wt- as well as ΔmiR-infected animals
compared to noninfected huNSG mice; however, in the absence of EBV miRNAs these
frequencies were signiﬁcantly lower than wt infection (Fig. S3A and C). CCR7
CD45RA central memory CD8 T cells were increased only in the spleen of wt
EBV-infected compared to noninfected mice (Fig. S3B) but not in the blood of wt
EBV-infected animals nor in either spleen or blood of ΔmiR EBV-infected animals
(Fig. S3B and D). The frequency of HLA-DR CD45RO CD4 T cells in both blood and
spleen did not correlate with EBV DNA loads in the matching organ for any of the
infected groups, except in blood for wt-infected mice (Fig. S3C and S2C). In contrast, the
frequency of HLA-DR CD45RO CD8 T cells in spleen and splenic EBV DNA load
correlated signiﬁcantly for all infection groups (Fig. 3D), while this correlation was
absent in the blood (Fig. S2D). This suggests that EBV viral loads primarily drive
activated CD8 T cell expansions. Therefore, the observed activation and memory
formation of CD8 T cells seem to correlate with EBV DNA burden, which might
indicate improved immune control by the less expanded CD8 T cells during ΔmiR
infection or decreased CD8 T cell expansion due to lower antigenic load.
Proliferation and LCL-speciﬁc cytokine production of CD8 T cells are lower in
miR than wt EBV-infected mice, whereas cytolytic granule contents of CD8 T
FIG 2 Reduced proliferation of EBV-infected cells in the absence of viral miRNAs. (A and B) Quantiﬁcation of the frequency of cleaved
caspase 3 (cl.Cas3) EBNA2 cells of all EBNA2 cells (n  6 to 7/group) (A) and representative immunohistochemistry for EBNA2 (brown)
and cl.Cas3 (red) (original magniﬁcation, 200) in splenic sections of huNSG mice infected with ΔmiR or wt EBV 5 to 6 weeks p.i. or
noninfected mice (mock) (B). (C and D) Quantiﬁcation of the frequency of Ki67 EBNA2 cells of all EBNA2 cells (n  6 to 7/group) (C)
and representative immunoﬂuorescence for EBNA2 (red), Ki67 (green), and DAPI (blue) (original magniﬁcation, 200) in splenic sections
of huNSG mice infected with ΔmiR or wt EBV 5 to 6 weeks p.i. or mock (D). (A and C) Pooled data from 3 experiments with mean  SEM
(unpaired t test with Welch’s correction).
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cells seem similar in the two infectious groups. To investigate the immune response
to EBV more thoroughly, we examined Ki67 and perforin expression in CD8 T cells on
splenic sections of infected huNSG mice. The frequency of CD8 T cells positive for the
cytolytic effector molecule perforin was signiﬁcantly increased in wt but not in ΔmiR
EBV-infected mice compared to noninfected controls, whereas no signiﬁcant difference
between wt and ΔmiR EBV-infected mice was observed (Fig. 4A and B, left panels).
Nevertheless, we detected a signiﬁcantly higher frequency of proliferating CD8 cells
in wt EBV-infected than ΔmiR EBV-infected mice or noninfected controls (Fig. 4A and B,
right panels). Additionally, we assessed EBV-speciﬁc T cell responses by coculturing
CD19 splenocytes with autologous LCLs generated with wt EBV and analyzed IFN-
release by ELISpot assay. Cocultures containing splenocytes isolated from wt-infected
mice showed signiﬁcantly increased EBV-speciﬁc T cell reactivity compared to cocul-
tures with splenocytes from ΔmiR-infected or mock-infected mice (Fig. 4C). However,
FIG 3 Activation and memory formation of CD8 T cells correlate with EBV viral load. (A and B) The frequency of
splenic HLA-DR CD45RO CD4 T cells (A) and splenic HLA-DR CD45RO CD8 T cells (B) of huNSG mice
infected with either 105 RIU of wt, ΔmiR, or ΔmiR-BART EBV 5 to 7 weeks p.i. or mock huNSG mice (n  7 to
18/group) was determined by ﬂow cytometry. (C and D) Correlation of the frequencies of activated memory CD4
(C) and activated memory CD8 (D) T cells, from panels A and C, respectively, with the splenic endpoint viral DNA
loads as determined by qPCR for each infected group. (A and B) Pooled data from 4 wt and ΔmiR-BART and 5 wt
and ΔmiR experiments with mean  SEM. *, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001, Mann-Whitney
U test. (C and D) Pooled data from 4 to 7 experiments. *, P 0.05; **, P 0.01, Spearman correlation.
Immune Escape by EBV miRNAs ®
January/February 2019 Volume 10 Issue 1 e01941-18 mbio.asm.org 5
 o
n
 January 30, 2020 at UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://m
bio.asm
.org/
D
ow
nloaded from
 
FIG 4 Proliferation and LCL-speciﬁc cytokine production of CD8 T cells are lower in ΔmiR than wt
EBV-infected mice, whereas cytolytic granule contents of CD8 T cells seem similar in the two infectious
groups. (A and B) Quantiﬁcation of the frequency of perforin CD8 cells of all CD8 cells or Ki67 CD8
cells of all CD8 cells (n  3 to 8/group) (A) and the representative immunohistochemistry staining with
CD8 (brown) and perforin (pink) (left column; original magniﬁcation, 200) or CD8 (brown) and Ki67
(pink) (right column; original magniﬁcation,200) in splenic sections of huNSG mice infected with either
ΔmiR or wt EBV 5 to 6 weeks p.i. or mock huNSG mice (B). (C) Evaluation of the EBV-speciﬁc T cell
response through the measurement of the IFN- release via ELISpot assay upon coculture of CD19
splenocytes, derived from ΔmiR or wt EBV-infected or noninfected (mock) huNSG mice, with autologous
(Continued on next page)
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splenocytes from ΔmiR-infected mice still produced signiﬁcantly more IFN- spots than
cells from noninfected mice (Fig. 4C). Thus, EBV-speciﬁc T cell responses were detected
in all infected groups but were higher in wt than in ΔmiR EBV-infected mice. Never-
theless, as shown in a previous study (12), we found increased IFN- release when
coculturing EBV-speciﬁc CD8 T cell clones with autologous ΔmiR LCL compared to
coculture with wt LCLs (Fig. 4D). This suggests that the less expanded CD8 T cell
compartment might control ΔmiR EBV-infected B cells more efﬁciently; even so, miRNA-
deﬁcient EBV infection induces less T cell proliferation, thereby accumulating fewer
cytololytic granule-containing and cytokine-producing CD8 T cells in vivo.
CD8 depletion rescues impaired infectious capacity of EBV devoid of its miR-
NAs. In order to address the T-cell-mediated immune control of ΔmiR EBV infection
more speciﬁcally, we depleted CD8 T cells with OKT8 antibodies before and during the
infection of huNSG mice with wt or ΔmiR EBV. Depletion of CD8 T cells led to similar
or even increased EBV loads in ΔmiR EBV-infected compared to wt EBV-infected huNSG
mice (Fig. 5A and B, left panels). Normalizing the viral loads to infected mice not treated
with OKT8 antibodies revealed that the fold increases over the average of the matching
FIG 4 Legend (Continued)
wt LCLs or medium (R10). (D) Assessment of the IFN- release via ELISA upon coculture of ΔmiR or wt
LCL with an EBNA1-speciﬁc CD8 T cell clone for 16 h. (A) Pooled data from 3 experiments represented
with the mean  SEM (*, P 0.05; **, P 0.01, unpaired t test with Welch’s correction). (C) Pooled data
from 5 experiments represented with the mean  SEM (*, P 0.05; ****, P 0.0001, Mann-Whitney U
test). (D) Data from 2 experiments (*, P 0.05, paired t test).
FIG 5 CD8 depletion rescues impaired viral infectious capacity of EBV devoid of its miRNAs. (A and B) Blood (A)
and spleen (B) DNA viral loads determined by qPCR of huNSG mice (n  5 to 14/group) infected with either wt or
ΔmiR EBV and treated with OKT8 for CD8 T cell depletion (left) or the matching relative viral loads normalized to
the mean of the corresponding nondepleted groups (n  8 to 12/group) with the indication of the fold difference
(red) for the different infection groups (right) 5 weeks p.i. (A) Horizontal dashed line indicates the lower limit of
quantiﬁcation (LLOQ). Values below the LLOQ were raised to the LLOQ and plotted on the LLOQ line. (C) Frequency
of tumor formation observed in mice infected with wt or ΔmiR EBV nontreated or treated with OKT8. (A and B)
Pooled data from 4 experiments with geometric mean (left) and arithmetic mean (right). *, P 0.05; **, P 0.01,
Mann-Whitney U test. (C) Pooled data from 4 experiments. *, P 0.05, Fisher’s exact test.
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nondepleted groups were signiﬁcantly higher, up to 240-fold, in the ΔmiR- compared
to wt-infected animals in blood and spleen (Fig. 5A and B, right panels). Hence, ΔmiR
EBV seems to be better controlled by CD8 T cells in vivo than wt EBV. Furthermore,
although ΔmiR EBV infection in huNSG mice never induced tumor formation in the
presence of an unmanipulated T cell compartment, upon OKT8 treatment tumor
incidence reached levels comparable to wt EBV-infected mice (Fig. 5C). Thus, these data
suggest that EBV miRNAs are able to reduce immune surveillance by T cells in vivo.
Absence of CD8 T cells alters CD4 T cell recognition of miRNA-deﬁcient EBV.
Since reduced frequencies of HLA-DR CD45RO T cells were observed in ΔmiR
compared to wt EBV-infected huNSG mice, we aimed to investigate whether the
absence of CD8 T cells changed CD4 T cell activation and memory formation.
Speciﬁcally, we explored HLA-DR and CD45RO expression on CD4 T cells. In both
blood and spleen, there was a trend toward higher frequencies of activated HLA-DR
CD4 T cells in ΔmiR compared to wt EBV-infected mice treated with OKT8, though no
signiﬁcant differences were observed (Fig. 6A and B). However, the frequency of
memory CD45RO CD4 T cells seemed comparable between ΔmiR- and wt-infected
mice inoculated with OKT8 (Fig. 6C and D). Nevertheless, we observed higher frequen-
cies of blood and splenic HLA-DR CD4 T cells (Fig. 6A and B) and higher frequencies
of blood and splenic CD45RO CD4 T cells in OKT8-treated wt and ΔmiR EBV-infected
mice compared to noninfected mice (Fig. 6C and D). Thus, the immune response to
ΔmiR EBV seems to generate a slightly higher activation and comparable memory
formation in the remaining T cells when depleted for CD8 T cells, suggesting that
CD4 T cells might also be more efﬁciently activated by ΔmiR EBV-infected cells.
FIG 6 Absence of CD8 T cells alters CD4 T cell recognition of EBV without viral miRNAs. The
frequencies of blood (A) and splenic (B) HLA-DR CD4 T cells and of blood (C) and splenic (D) CD45RO
CD4 T cells of huNSG mice infected with either wt or ΔmiR EBV treated with OKT8 for CD8 T cell
depletion 5 weeks p.i. (n  3 to 13/group) as determined by ﬂow cytometry. (A to D) Pooled data from
2 to 3 experiments with mean  SEM. *, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001, Mann-
Whitney U test.
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DISCUSSION
EBV was among the ﬁrst viruses which were described to express miRNAs (21, 22). A
wide spectrum of cellular, host, and viral functions have been described to be regulated by
at least 44 mature miRNAs that EBV expresses (3, 23). Our in vivomodel of EBV infection in
huNSG mice now reveals that the main outcome of loss of miRNA expression is elevated
T-cell-mediated immune control of viral infection and associated tumorigenesis. This im-
proved immune control is associated with decreased numbers of proliferating EBV-infected
B cells and attenuated T cell expansion. Consistent with a previous study that already
demonstrated delayed kinetics of EBV infection and a tendency toward lower virus-
associated lymphomagenesis in the absence of the BHRF1 miRNAs (14), we also ﬁnd
reduced viral loads and no detectable tumorigenesis with the complete miRNA-deﬁcient
virus but unchanged infection with BART miRNA knockout EBV. Furthermore, deletion of
the EBERs, another prominent species of EBV-expressed nontranslated RNAs, has also no
signiﬁcant effect on EBV infection in huNSGmice (24). This suggests that the BHRF1miRNAs
inﬂuence viral infection and tumor formation more strongly than EBERs or the BART
miRNAs, and this regulation mainly affects T cell recognition.
Immune evasion by miRNAs affects all stages of the EBV life cycle because it also covers
the latent EBV infection programs that are important for the virus to persist, while most of
the immune evasive proteins encoded by the virus are expressed only during lytic repli-
cation. These fall into four categories, inhibiting immune sensing via Toll-like receptors
(TLRs) and the downstream NF-B activation, compromising the type I IFN response,
downregulating MHC-restricted antigen presentation, and changing a pro- into an anti-
inﬂammatory environment (25). For example, BGLF5 and BPLF1 downregulate TLRs or
interfere with TLR-mediated NF-B activation (26, 27). Furthermore, BZLF1, BRLF1, BILF1,
and BGLF4 reduce expression or inhibit the function of interferon-responsive factors (IRFs)
3 and 7 to compromise type I IFN responses (28–31). EBV also encodes BNLF2a, a protein
that blocks peptide import into the endoplasmic reticulum (ER) via the transporter associ-
ated with antigen presentation (TAP) (32–35); BILF1, a protein that reduces MHC class I
surface levels (34, 36, 37); BZLF2, a protein that interferes with T cell receptor binding to
MHC class II (38, 39); and BDLF3, a protein that shields MHC class I- and II-restricted antigen
presentation from T cell recognition (40). Finally, EBV-infected cells secrete a soluble
macrophage colony-stimulating factor (M-CSF) receptor that is encoded in the BARF1 gene
(41, 42) and viral IL-10 from the BCRF1 gene (43), which reduce inﬂammation and thereby
immune surveillance of infected cells. In contrast, latent EBV proteins mainly diminish their
own antigen presentation in cis, by limiting their protein expression and/or actively
inhibiting their proteasomal degradation, as is the case for EBNA1 (44, 45). Thus, virally
encoded proteins contribute to immune evasion in transmainly during lytic EBV replication,
while nontranslated miRNAs might primarily serve this purpose during latent EBV infection.
For this purpose, EBV miRNAs attenuate viral antigen production, compromise MHC
class I-restricted antigen presentation via TAP downregulation and MHC class II-
restricted antigen presentation via inhibition of lysosomal degradation, and diminish
production of the T cell chemoattractant CXCL11 and the T-cell-priming cytokine IL-12
(3). For antigen recognition by CD8 T cells, primarily TAP2 mRNA downregulation and
targeting by the RNA-induced silencing complex (RISC) have been identiﬁed as viral
miRNA targets (12). This diminishes also TAP1 protein levels as well as surface expres-
sion of especially HLA-B molecules, which are the main MHC class I restriction elements
of immunodominant EBV-speciﬁc CD8 T cell responses (46). Even though our T cell
depletion experiments clearly argue that such miRNA functions dominate the outcome
of EBV infection at week 5 with respect to viral loads and tumor formation, other
previously in vitro-deﬁned functions of EBV miRNAs might be responsible for the lower
viral loads that we detect already at week 3 after infection. At this 3-week time point,
lytic replication contributes to viral loads in our in vivo model of EBV infection, as could
be demonstrated by comparing wild-type with lytic-replication-deﬁcient (BZLF1 knock-
out) virus (16). Along these lines, sumoylation seems to be required for infectious virus
production, and the SUMO ligase RNF4 is downregulated by the BHRF1-1 miRNA (47).
Immune Escape by EBV miRNAs ®
January/February 2019 Volume 10 Issue 1 e01941-18 mbio.asm.org 9
 o
n
 January 30, 2020 at UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://m
bio.asm
.org/
D
ow
nloaded from
 
This could suggest that diminished lytic EBV replication could contribute to the lower
viral loads at week 3 after infection. Furthermore, BHRF1 miRNAs of EBV have been
suggested to be required for efﬁcient B cell transformation by attenuating viral protein
expression (20, 48). They seem to optimize the expression timing of EBNA-LP and
BHRF1, a viral antiapoptotic Bcl-2 homologue, in cis, when they get processed from the
transcripts of these viral proteins that also contain their pri-miRNAs (49, 50). Also, these
mechanisms might contribute to the diminished viral loads upon miRNA-deﬁcient EBV
infection in huNSG mice at early time points after infection. However, these defects
seemed to be transient in vitro, and no growth defects could be detected in established
EBV-transformed B cell lines. Similarly, in our studies at 5 weeks postinfection miRNA-
mediated attenuation of T cell responses predominated and viral loads as well as tumor
formation by ΔmiR EBV could be restored by T cell depletion. Thus, miRNA deﬁciency
could be further explored to promote immune responses with an attenuated EBV that
might be considered for prophylactic vaccination against symptomatic primary infec-
tion, i.e., infectious mononucleosis.
MATERIALS AND METHODS
Recombinant EBV. Concentrates of the green ﬂuorescent protein (GFP)-encoding Epstein-Barr virus
(EBV) miRNA knockout (ΔmiR, p4027), EBV BART miRNA knockout (ΔmiR-BART, p5446), or EBV wild-type
(wt, p2089) viruses were prepared as preciously described (12, 13, 51) and titrated on Raji cells. The
miRNA-expressing loci in the ΔmiR and ΔmiR-BART viruses were replaced with computed scrambled
sequences as described previously (15). The GFP-expressing cells were quantiﬁed by ﬂow cytometry
2 days later to calculate Raji-infecting units (RIU). For in vitro infection of B cells, B cells isolated from
splenocytes or human PBMCs were isolated using anti-CD19 microbeads (Miltenyi Biotec) and infected
with wt or ΔmiR EBV with the addition of a CD40L-expressing feeder cell line irradiated with 140 Gy. The
cells were maintained in RPMI 1640 medium (Gibco, Thermo Fisher Scientiﬁc) with 10% FCS, strepto-
mycin, and penicillin in the absence of the CD40L-expressing feeder cell line. Total numbers of
established LCLs were determined by trypan blue staining.
Mice with reconstituted human immune system components and infection with EBV. NOD-scid
c
null (NSG) mice and HLA-A2 transgenic NSG mice were obtained from the Jackson Laboratories and
maintained under speciﬁc-pathogen-free conditions. Reconstitution was performed as previously de-
scribed (52). Reconstitution level was checked 10 to 12 weeks later and again a week prior to the start
of the experiments by ﬂow cytometric immune phenotyping of peripheral blood as previously described
(16). Mice were infected intraperitoneally with 1 105 RIU of wt, ΔmiR, or ΔmiR-BART EBV and followed
for 5 or 6 weeks. Samples below the lower limit of quantiﬁcation (LLOQ) of 67 EBV DNA copies were
considered negative for EBV DNA. The value of the LLOQ was used for the blood DNA copies of mice
having a viral load in the spleen but not in the blood. Mice without any viral loads in the blood and
spleen throughout the experiment were considered not infected and excluded from the analysis.
Puriﬁcation of mouse anti-human CD8 antibody. OKT8 hybridoma cells (mouse IgG2a; ATCC,
Manassas, VA, USA) were gradually adapted to serum- and protein-free PFHM-II medium (Thermo Fisher
Scientiﬁc [formerly Gibco], catalog no. 12040-077). Cells were cultured in BD CELLine 1000 ﬂasks (BD catalog
no. 353137) according to the manufacturer’s recommendation. Antibodies were precipitated from the culture
supernatant by addition of an equal volume of saturated ammonium-sulfate solution. After buffer exchange
to PBS using PD-10 desalting columns (Sephadex G25 medium; GE Healthcare), antibodies were sterilized by
ﬁltration through 0.2-m ﬁlters (Filtropur S 0.2; Sarstedt) and stored at 4°C until use.
Depletion of T cells. Human CD8 T cells were depleted in mice before EBV infection by intraperi-
toneal injection of 100 g OKT8 antibodies on three consecutive days. To deplete T cells for the duration
of the experiment, 50 g of the depletion antibodies was injected 3 times a week starting 2 weeks
postinfection until the day of sacriﬁce.
Quantiﬁcation of viral load. DNA from splenic tissue was obtained using a QIAamp DNA tissue kit
(Qiagen) and from whole blood using the NucliSENS EasyMAG System (bioMérieux), both according to
the manufacturers’ recommendations. The TaqMan (Applied Biosystems) real-time PCR technique was
performed to quantitatively analyze EBV DNA as previously described (53), with modiﬁed primers for the
BamHI W fragment (5=-CTTCTCAGTCCAGCGCGTTT-3= and 5=-CAGTGGTCCCCCTCCCTAGA-3=) and a ﬂuo-
rogenic probe (5=-FAM-CGTAAGCCAGACAGCAGCCAATTGTCAG-TAMRA-3=). All PCRs were run on an ABI
Prism 7300 Sequence Detector or ViiA7-240 Real-Time PCR system (Applied Biosystems), and samples
were analyzed in duplicate.
Flow cytometry. All ﬂuorescently labeled antibodies are listed in Table S1 in the supplemental material.
Lysis of erythrocytes in whole blood was done with NH4Cl. Spleens were mashed and ﬁltered through a
70-m cell strainer before separation of mononuclear cells on Ficoll-Paque gradients. Cell suspensions were
stained with antibodies for 30min at 4°C, washed, and analyzed on FACS Canto or LSR Fortessa cytometers
(BD Biosciences). Analysis of ﬂow cytometric data was performed with FlowJo (Tree Star).
Histology, immunohistochemistry, and immunoﬂuorescence. Tissue was ﬁxed in 10% saline-
buffered formalin and parafﬁn embedded. For immunohistochemistry and immunoﬂuorescence, 3-m
sections were processed on a Leica Bond-Max or Bond-III automated immunohistochemistry system.
Stainings were performed with monoclonal mouse anti-EBNA2 (clone PE2; Abcam), rabbit anti-Ki67
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(clone SP6; Cell Marque), rabbit anti-huCD8 (clone SP16; Marque), mouse antiperforin (5B10; Novocastra
Laboratories), and polyclonal cleaved caspase 3 (Cell Signaling Technology). For immunoﬂuorescence,
the AF488 donkey anti-rabbit IgG (Jackson ImmunoResearch), DyLight549 horse anti-mouse IgG (Vec-
trolabs), and DAPI (Sigma) were used. Stainings were analyzed as described elsewhere (52) using the
Vectra3 automated quantitative pathology imaging system (PerkinElmer) and InForm software analysis
(PerkinElmer). The percentage of EBNA2 plus Ki67, EBNA2 plus cleaved caspase 3, huCD8 plus Ki67, or
huCD8 plus perforin double-positive cells of all EBNA2- or huCD8-positive cells was calculated.
EBV-speciﬁc IFN- release assay (ELISpot). EBV-speciﬁc T cell responses were analyzed using an
IFN- enzyme-linked immunospot (ELISpot) assay as previously described (10, 54). Brieﬂy, splenocytes
were depleted of human CD19 cells using anti-CD19 microbeads (Miltenyi Biotec). The CD19-depleted
fraction was stimulated with autologous LCLs at a ratio of 1:4 for 18 h, and incubation with R10 and
phorbol myristate acetate (PMA)-ionomycin served as negative and positive controls, respectively. Each
condition was performed in duplicates. Spots were counted on an ELISpot reader system (ELR02;
Autoimmun Diagnostika GmbH).
CD8 T cell cloning and restimulation. CD8 T cell clones speciﬁc for the nuclear antigen 1 of EBV
(EBNA1) were generated from freshly isolated PBMCs which were depleted of CD4 T cells using
anti-CD4-conjugated MACS microbeads and magnetic selection (Miltenyi Biotec). PBMCs were stimulated
with 5 M EBNA1-derived HPVGEADYFEY peptide (aa 407 to 417) for 3 to 4 h. Responding cells were
enriched by IFN- secretion assay (130-054-201; Miltenyi Biotec) and were cloned by limiting dilution at
3 and 30 cells per well on HLA-matched irradiated LCLs (104/well) loaded with the relevant peptide at
5 M and allogeneic irradiated, PHA-treated PBMCs (105/well) in medium with 10% pooled human sera
supplemented with 150 IU/ml IL-2 (T cell medium). Growing microcultures were screened for peptide
reactivity by IFN- ELISA (3420-1H-20; Mabtech). Selected CD8 T cell clones were further expanded on
autologous irradiated LCLs loaded with the relevant peptide at 5 M and allogeneic irradiated, PHA-
treated PBMCs in T cell medium. Clones were maintained in T cell medium. Every 2 to 3 weeks, CD8 T
cell clones were restimulated with peptide-pulsed autologous LCLs and allogeneic PHA-treated PBMCs.
The resulting CD8 T cell clone used in this study was speciﬁc for EBNA1407–417 (HPVGEADYFEY,
HLA-B*3501). To investigate speciﬁc recognition of target cells, 10,000 CD8 T cell clones were cocul-
tured with 100,000 autologous wt or ΔmiR LCLs. After overnight incubation, coculture supernatants from
single wells were tested by ELISA for IFN- content.
Statistical analysis. Statistical analysis and graph preparation were performed with Prism software
(GraphPad). A paired t test, unpaired t test with Welch’s correction, or two-tailed Mann-Whitney U test
was used. A P value of 0.05 was considered statistically signiﬁcant.
Study approval. All animal protocols were approved by the cantonal veterinary ofﬁce of the canton
of Zürich, Switzerland (protocols 209/2014 and 159/2017). All studies involving human samples were
reviewed and approved by the cantonal ethics committee of Zürich, Switzerland (protocol KEK-StV-
Nr.19/08).
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Volume 10, no. 1, e01941-18, 2019, https://doi.org/10.1128/mBio.01941-18. After
careful review of Fig. 3, it was noted that for the middle panels of Fig. 3C and D P values
instead of r values had been reported. The revised Fig. 3 shown here reports the
corrected r values for the correlations of ΔmiR EBV DNA copies/spleen with the
percentage of splenic HLA-DR CD45RO CD4 T cells (Fig. 3C) and with the percent-
age of splenic HLA-DR CD45RO CD8 T cells (Fig. 3D).
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FIG 3 Activation and memory formation of CD8 T cells correlate with EBV viral load. (A and B) The frequency of
splenic HLA-DR CD45RO CD4 T cells (A) and splenic HLA-DR CD45RO CD8 T cells (B) of huNSG mice
infected with either 105 RIU of wt, ΔmiR, or ΔmiR-BART EBV 5 to 7 weeks p.i. or mock huNSG mice (n  7 to
18/group) was determined by ﬂow cytometry. (C and D) Correlation of the frequencies of activated memory CD4
(C) and activated memory CD8 (D) T cells, from panels A and B, respectively, with the splenic endpoint viral DNA
loads as determined by qPCR for each infected group. (A and B) Pooled data from 4 wt and ΔmiR-BART and 5 wt
and ΔmiR experiments with mean  SEM. *, P  0.05; **, P  0.01; ***, P  0.001; ****, P  0.0001, Mann-Whitney
U test. (C and D) Pooled data from 4 to 7 experiments. *, P  0.05; **, P  0.01, Spearman correlation.
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